Guo et al. demonstrated that a half-life-extended IL-10/Fc fusion protein could directly invigorate terminally exhausted CD8+ tumor-infiltrating lymphocytes (TILs) via oxidative phosphorylation and the process is in absence of the progenitor cells, making it a promising complementary therapy to immune checkpoint blockade in the treatment of patients with poor or none tumor infiltration of progenitor-exhausted CD8+ TILs [109]. The gene discussed is IL10; the disease is neoplasm.